Concurrent use is mechanistically redundant and amplifies negative feedback suppression
Melanotan 2 Nasal Spray 10MG: Key Research Facts MT-II acts as a non-selective agonist across multiple melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R with binding affinities documented in multiple in vitro receptor characterisation studies
1 Select confirmatory secondary endpoints included the proportion of participants achieving 10%, 15%, 20% and 25% weight loss, with semaglutide 7.2 mg vs placebo (and for 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg)
The highest dosage provides the strongest impact on reducing appetite and significantly lowering body weight
3,5 Hydration, Fiber, and GI Support: 6 GLP-1 therapies may blunt thirst, increasing dehydration risks